이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Spero Therapeutics 관리
관리 기준 확인 2/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Sath Shukla
최고 경영자
US$2.0m
총 보상
CEO 급여 비율 | 25.9% |
CEO 임기 | less than a year |
CEO 소유권 | n/a |
경영진 평균 재임 기간 | 1.6yrs |
이사회 평균 재임 기간 | 10.2yrs |
최근 관리 업데이트
Recent updates
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Apr 23Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%
Mar 12Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Jan 02Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates
May 18Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth
Apr 17Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%
Apr 13We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth
Apr 05Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value
Oct 03Spero Therapeutics appoints Kamal Hamed MD CMO
Sep 15Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate
Sep 06Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M
Aug 10We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate
Jul 04We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely
Mar 17Sizing Up Spero Therapeutics
Oct 15Spero Therapeutics, Inc.'s (NASDAQ:SPRO) CEO Compensation Looks Acceptable To Us And Here's Why
Aug 11CEO 보상 분석
날짜 | 총 보상 | 급여 | 회사 수익 |
---|---|---|---|
Mar 31 2024 | n/a | n/a | US$23m |
Dec 31 2023 | US$2m | US$524k | US$23m |
Sep 30 2023 | n/a | n/a | -US$2m |
Jun 30 2023 | n/a | n/a | -US$10m |
Mar 31 2023 | n/a | n/a | -US$27m |
Dec 31 2022 | US$2m | US$478k | -US$46m |
Sep 30 2022 | n/a | n/a | -US$102m |
Jun 30 2022 | n/a | n/a | -US$113m |
Mar 31 2022 | n/a | n/a | -US$103m |
Dec 31 2021 | US$2m | US$441k | -US$90m |
보상 대 시장: Sath 의 총 보상 ($USD 2.02M )은 US 시장( $USD 683.56K ).
보상과 수익: Sath 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Sath Shukla (51 yo)
less than a year
테뉴어
US$2,024,647
보상
Mr. Satyavrat Shukla, also known as Sath, C.F.A., has been President, Chief Executive Officer and Director at Spero Therapeutics, Inc. since August 1, 2023. He had been the Chief Financial Officer of Spero...
리더십 팀
이름 | 위치 | 테뉴어 | 보상 | 소유권 |
---|---|---|---|---|
Co-Founder & Chairman of the Board | 10.8yrs | US$2.39m | 0.41% $ 285.8k | |
President | less than a year | US$2.02m | 데이터 없음 | |
Chief Operating Officer | 1.4yrs | US$1.44m | 0.12% $ 83.0k | |
CFO, Chief Business Officer & Treasurer | less than a year | 데이터 없음 | 데이터 없음 | |
Chief Human Resource Officer | 2.7yrs | 데이터 없음 | 데이터 없음 | |
Chief Medical Officer | 1.8yrs | 데이터 없음 | 0.22% $ 157.8k |
1.6yrs